NasdaqGS:ONCBiotechs
Sonrotoclax Trial Success Might Change The Case For Investing In BeOne Medicines (ONC)
In August 2025, BeOne Medicines announced that its investigational BCL2 inhibitor sonrotoclax achieved positive topline results in a Phase 1/2 study for relapsed or refractory mantle cell lymphoma, meeting its primary endpoint and showing clinically meaningful benefit in a heavily pretreated patient group.
With regulatory submissions planned in multiple regions and acceptance for accelerated review in the US and China, sonrotoclax is positioned as a potential new treatment option within...